MDUFA VI Negotiations Focus on TAP Expansion, Fee Structures
The latest round of MDUFA VI negotiations discussed different perspectives between the FDA and industry on TAP 2.0 and the agency’s proposals for enhancing the program.
Medtech Insight - February 26, 2026

Execs On The Move: February 16–20, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - February 26, 2026

Medtronic’s MiniMed Sets IPO Price Range at Up to $784M As Layoffs Hit At California Headquarters
Medtronic plans to retain about 90% of the newly standalone MiniMed. While MiniMed’s 2025 revenues totaled $2.7bn, the company still posted a net loss amid strong competition from Abbott and Dexcom and recently announced more than six dozen layoffs at its California plant.
Medtech Insight - February 26, 2026

Biopharma Holding Up Well Against Other Industries In Eyes Of Investors
Sonia Gupta of Goldman Sachs offered an optimistic view of biopharma versus high-tech investments during a capital markets update at Biocom’s annual Global Partnering and Investor Conference.
Scrip - February 26, 2026

Bimzelx Sales Sail Past €2bn At Buoyant UCB
The drug’s launch for hidradenitis suppurativa has been particularly impressive.
Scrip - February 26, 2026

Quotables: Pharma Leaders On The Month’s Hot Topics
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
Scrip - February 26, 2026

Haleon Held Back By Cautious Consumers
Haleon's growth rate suffered in 2025 as consumer confidence sank in key markets like North America and Europe.
HBW Insight - February 26, 2026

Senate HELP Report Maps US FDA Reform Agenda Ahead of User Fee Reauthorizations
The proposals are aimed at ensuring a more consistent, predictable review process for new drug applications, onshoring more Phase I trials, codifying agency measures to encourage rare disease drug development, and encouraging biosimilar and generic competition.
Generics Bulletin - February 26, 2026

Sarepta CEO Ingram Steps Down As Dystrophy Strikes Close To Home
The controversial Doug Ingram will depart for personal reasons, following the diagnosis of two family members with myotonic dystrophy.
Scrip - February 26, 2026

Sandoz To Lift Capital Spending Beyond $1bn To Fuel Biosimilar Ambitions
Sandoz enjoyed good sales and profit growth in 2025, with a significant increase in free cash flow allowing the firm to continue investing in its major European biosimilars manufacturing network.
Generics Bulletin - February 26, 2026

EU Urban Wastewater Directive: With EFPIA’s Case Dismissed, Fight Now With Poland
With EFPIA’s challenge struck out, the UWWTD battle now shifts to Poland’s case at the Court of Justice, where AESGP expects the Directive’s core legal arguments to finally be tested.
HBW Insight - February 26, 2026

Asahi Kasei Boosts Global Presence, Infection Business With Acquisition Of Germany’s AiCuris
Asahi Kasei’s €780m acquisition of AiCuris strengthens its anti?infectives portfolio through immediate Prevymis royalties and the near?term commercial potential of pritelivir.
Scrip - February 26, 2026

Podcast: Affibody And The Case For Antibody Mimetics In Radioligand Therapy
Swedish biotech Affibody is using tiny engineered proteins to expand radioligand therapy's target space. CEO David Bejker details its HER2 program, Albumod technology and partnership strategy.
In Vivo - February 26, 2026

How Asia’s Biopharma Transformation Is Reshaping Global Deal Flow
A decade ago, China was buying Western drugs. Now it is selling them. Executives who ignore the shift do so at their peril.
In Vivo - February 26, 2026

Beijing Health Guard’s Trial Pauses Add To China HPV Vaccine Makers’ Distress
Amid a wider domestic market downturn, Beijing Health Guard’s three Phase III trials for two of its HPV vaccine candidates were suspended in January and February due to overdue payments to sites.
Scrip - February 26, 2026

US Hemp Supplement Market Forecast: Congress Delays THC Level Changes, Or ‘Payments Dry Up’?
When House Agriculture Committee on March 3 considers five-farm bill year reauthorization, it will vote whether to add an amendment to extend by a year the Nov. 12 deadline for compliance with lower limits on all THC levels allowed in lawful hemp.
HBW Insight - February 26, 2026